Abstract
Background Ethnically diverse and socio-economically deprived communities have been differentially affected by the COVID-19 pandemic in the UK.
Method Using a multilevel regression model we assess the time-varying association between SARS-CoV-2 infections and areal level deprivation and ethnicity. We separately consider weekly test positivity rate (number of positive tests over the total number of tests) and estimated unbiased prevalence (proportion of individuals in the population who would test positive) at the Lower Tier Local Authority (LTLA) level. The model also adjusts for age, urbanicity, vaccine uptake and spatio-temporal correlation structure.
Findings Comparing the least deprived and predominantly White areas with most deprived and predominantly non-White areas over the whole study period, the weekly positivity rate increases by 13% from 2·97% to 3·35%. Similarly, prevalence increases by 10% from 0·37% to 0·41%. Deprivation has a stronger effect until October 2020, while the effect of ethnicity becomes slightly more pronounced at the peak of the second wave and then again in May-June 2021. Not all BAME groups were equally affected: in the second wave of the pandemic, LTLAs with large South Asian populations were the most affected, whereas areas with large Black populations did not show increased values for either outcome during the entire period under analysis.
Interpretation At the area level, IMD and BAME% are both associated with an increased COVID-19 burden in terms of prevalence (disease spread) and test positivity (disease monitoring), and the strength of association varies over the course of the pandemic. The consistency of results across the two outcome measures suggests that community level characteristics such as deprivation and ethnicity have a differential impact on disease exposure or susceptibility rather than testing access and habits.
Fundings EPSRC, MRC, The Alan Turing Institute, NIH, UKHSA, DHSC, NIHR
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
BL was supported by the UK Engineering and Physical Sciences Research Council through the Bayes4Health programme [Grant number EP/R018561/1] and gratefully acknowledges funding from Jesus College, Oxford. SR is supported by MRC programme grant MC\_UU\_00002/10; The Alan Turing Institute grant: TU/B/000092; EPSRC Bayes4Health programme grant: EP/R018561/1. GN and CH acknowledge support from the Medical Research Council Programme Leaders award MC_UP_A390_1107. CH acknowledges support from The Alan Turing Institute, Health Data Research, U.K., and the U.K.Engineering and Physical Sciences Research Council through the Bayes4Health programme grant. MB acknowledges partial support from the MRC Centre for Environment and Health, which is currently funded by the Medical Research Council (MR/S019669/1). MB and TP were partially supported by the National Institutes of Health, grant: R01HD092580-01A1. Infrastructure support for the Department of Epidemiology and Biostatistics is also provided by the NIHR Imperial BRC. Authors in The Alan Turing Institute and Royal Statistical Society Statistical Modelling and Machine Learning Laboratory gratefully acknowledge funding from Data, Analytics and Surveillance Group, a part of the UKHSA. This work was funded by The Department for Health and Social Care with in-kind support from The Alan Turing Institute and The Royal Statistical Society.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research has been approved by the Alan Turing Institute's Ethics Advisory Group, nb C2103-105.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵+ Members of The Alan Turing Institute and Royal Statistical Society’s “Statistical Modelling and Machine Learning Laboratory”, in partnership with the Data, Analytics and Surveillance Group, a part of the UKHSA.
